Abstract
The integrity of, and public respect for, clinical research and professional education is endangered by inadequate attention to possible conflicts of interest and conflicts of commitment. All funding sources carry some risk of encouraging “incentive bias,” and no reasonable critics have proposed doing away with pharmaceutical company sponsorship of research and training. Several have urged the pharmaceutical industry to assume a more responsible role in addressing these ethical concerns, even arguing that this industry “should be held to owe a duty of utmost good faith and concern (’fiduciary duty’) for consumers’ safety and well being” (Shimm et al., 1996b). However, the larger burden of responsibility falls on professionals who clearly have a fiduciary duty to place the interests of patients, research subjects, and science above personal welfare.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
